TriSalus Life Sciences In... (TLSI)
TriSalus Life Sciences Statistics
Share Statistics
TriSalus Life Sciences has 32.27M shares outstanding. The number of shares has increased by 12.27% in one year.
| Shares Outstanding | 32.27M |
| Shares Change (YoY) | 12.27% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 8.77% |
| Shares Floating | 13.43M |
| Failed to Deliver (FTD) Shares | 171 |
| FTD / Avg. Volume | 0.33% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -16.82. TriSalus Life Sciences's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -16.82 |
| PS Ratio | 0 |
| Forward PS | 1 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for TriSalus Life Sciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.06, with a Debt / Equity ratio of -0.91.
| Current Ratio | 0.06 |
| Quick Ratio | 0 |
| Debt / Equity | -0.91 |
| Debt / EBITDA | -0.65 |
| Debt / FCF | -0.58 |
| Interest Coverage | -11.7 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $267.55K |
| Profits Per Employee | $-302.12K |
| Employee Count | 110 |
| Asset Turnover | 1.23 |
| Inventory Turnover | 6.29 |
Taxes
| Income Tax | 6K |
| Effective Tax Rate | -0.02% |
Stock Price Statistics
The stock price has increased by -45.49% in the last 52 weeks. The beta is 0.49, so TriSalus Life Sciences's price volatility has been higher than the market average.
| Beta | 0.49 |
| 52-Week Price Change | -45.49% |
| 50-Day Moving Average | 5.5 |
| 200-Day Moving Average | 4.98 |
| Relative Strength Index (RSI) | 57.49 |
| Average Volume (20 Days) | 51.34K |
Income Statement
In the last 12 months, TriSalus Life Sciences had revenue of 29.43M and earned -33.23M in profits. Earnings per share was 0.
| Revenue | 29.43M |
| Gross Profit | 25.33M |
| Operating Income | -36.16M |
| Net Income | -33.23M |
| EBITDA | -36.16M |
| EBIT | -33.13M |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 8.53M in cash and 23.63M in debt, giving a net cash position of -15.1M.
| Cash & Cash Equivalents | 8.53M |
| Total Debt | 23.63M |
| Net Cash | -15.1M |
| Retained Earnings | -279.55M |
| Total Assets | 23.97M |
| Working Capital | -9.58M |
Cash Flow
In the last 12 months, operating cash flow was -40.84M and capital expenditures 0, giving a free cash flow of -40.84M.
| Operating Cash Flow | -40.84M |
| Capital Expenditures | 0 |
| Free Cash Flow | -40.84M |
| FCF Per Share | 0 |
Margins
Gross margin is 86.06%, with operating and profit margins of -122.88% and -112.92%.
| Gross Margin | 86.06% |
| Operating Margin | -122.88% |
| Pretax Margin | -102.07% |
| Profit Margin | -112.92% |
| EBITDA Margin | -122.88% |
| EBIT Margin | -122.88% |
| FCF Margin | -138.78% |
Dividends & Yields
TLSI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for TLSI is $11, which is 97.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $11 |
| Price Target Difference | 97.8% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -17.16 |
| Piotroski F-Score | 2 |